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Aromatase Inhibitor Exemestane has Antiproliferative Effects
on Human Mesothelioma Cells
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Carmen D’Angelo, BSc,‡ Paola Muti, MD,§ Alessandra Verdina, BSc,* Ada Sacchi, BSc,*
Bruno Vincenzi, MD, Alfonso Baldi, MD,¶ and Rossella Galati, BSc*
Purpose: The aim of this study was to investigate the expression
and biological activity of aromatase (CYP19A1) in malignant me-
sothelioma (MM).
Experimental Design:We found CYP19A1 in five human MM cell
lines using reverse transcription polymerase chain reaction and
Western immunoblots and in a group of samples from patients with
MM by immunohistochemistry. Aromatization activity was determined
in MM cells by enzyme-linked immunosorbent assay as a measure of
estradiol (E2) product, in basal condition and after addition of cytokine,
prostaglandin-E2, and epidermal growth factor to MM cells. Treatment
of MM cells with exemestane, a CYP19A1 inhibitor, was assessed by
cell proliferation kit, cell cycle analysis, and Western blot for caspase,
poly(ADP-ribose)polymerase, Bcl-xL, and v-akt murin thymoma viral
oncogene homolog (Akt).
Results: Biological activity of CYP19A1, already present in basal
condition, was increased in MPP89 and Ist-Mes1 cells after treat-
ment with cytokine, in all MM cells on prostaglandin-E2 treatment,
and in MPP89, Ist-Mes2, and Ist-Mes1 after addition of epidermal
growth factor. Treatment of MM cells with exemestane led to
significant reduction of tumor cell growth, perturbation of cell cycle,
caspase activation, poly(ADP-ribose)polymerase cleavage, and
down-regulation of phosphorylation of Akt and Bcl-xL. In tumor
tissues, we found a cytoplasmic localization of CYP19A1. By
univariate analysis, overall survival resulted to be strongly influ-
enced by high CYP19A1 expression (p  0.001).
Conclusion: These findings show that CYP19A1 is present inMM and
that cell growth can be down-regulated by exemestane. As Akt pathway
and Bcl-xL are implicated in conferring resistance to conventional
chemotherapy, exemestane could open new treatment strategies to be
associated with standard therapy for patients afflicted with MM.
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Aromatase (CYP19A1) is the cytochrome P450 enzymecomplex that converts C19 androgens to C18 estrogens.
The human CYP19A1 gene, located in the 21.2 region on the
long arm of chromosome 15 (15q21.2), spans a region that
consists of a 30 kb coding region and a 93 kb regulatory
region. Its regulatory region contains at least 10 distinct
promoters regulated in a tissue- or signaling pathway-specific
manner. Each promoter is regulated by a distinct set of
regulatory sequences in DNA and transcription factors that
bind to these specific sequences. These partially tissue-spe-
cific promoters are used in the gonads, bone, brain, vascular
tissue, adipose tissue, skin, fetal liver, and placenta for
estrogen biosynthesis necessary for human physiology.1 Es-
trogens contribute to differentiation and maturation in normal
lung2 and also stimulate growth and progression of lung
tumors.3,4 These biological effects are mediated by estrogen
receptors (ERs), with ER transcripts and proteins reported in
most non-small cell lung cancers.3,4 As in breast, CYP19A1
mediates synthesis of estrogens in lung tissues,4,5 and local
production of estrogens in women and in men could affect
lung tumor progression in ER-expressing malignancies.4,6
Cytokines, such as interleukin (IL)-6 and tumor necrosis factor
(TNF)-, have an important role in regulating estrogen synthesis
in peripheral tissues. The activity of the CYP19A1 is increased
by IL-6 and TNF-.7 Multiple factors, including epidermal
growth factor (EGF) and prostaglandin-E2 (PGE2), would syn-
ergistically up-regulate CYP19A1 expression.8–10
Pleural mesothelioma is not just a limiting protective
layer for lung but a dynamic cellular structure regulating
serial responses to injury, infection, and disease. Mesothelial
cells are biologically active because they can sense and
respond to signals within their microenvironment. The devel-
opment of malignant mesothelioma (MM) is associated in
most patients with a history of asbestos exposure.11 Research
has demonstrated that asbestos exposure generates reactive
oxygen species and activates macrophages and other cell
types to produce these compounds, and cytokines and growth
factors.12 Furthermore, the deposition of insoluble amphibole
fibers results in a chronic inflammatory state in exposed
individuals.13 The existence of inflammation has been asso-
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ciated with up-regulation of the inducible cyclooxygenase-2,
leading to an increase in its product PGE2,14 and is associated
with an increased risk of cancer.15 Even with widespread
asbestos abatement efforts, the increase in MM incidence is
likely to continue in Western Europe and the United States
well into the next decade, and projections suggest that the
incidence will peak around 2020.16 Other factors, such as
chemical carcinogens, ionizing radiation, chronic inflamma-
tion, and SV40 viral exposure, may contribute to the devel-
opment of MM.17 Pleural MM is 10- to 30-fold more com-
mon than their peritoneal counterparts.18,19 Regardless of site
of origin, the prognosis is usually poor with a median survival
of 4 to 12 months for pleural tumors20 and less than 1 year for
peritoneal tumors.19 Systemic chemotherapy and radiation do
little to improve the outcome. The resistance to conventional
chemotherapy and most chemotherapeutic agents have been
attributed to activation of v-akt murin thymoma viral onco-
gene homolog (Akt) and overexpression of prosurvival Bcl2
family members, such as Bcl-xL and Bcl2.21,22 The phospha-
tidylinositol 3-kinase/Akt signaling pathway regulates funda-
mental cellular processes linked to tumorigenesis, including
cell cycle progression; cell survival, adhesion, motility, and
spreading; angiogenesis; glucose homeostasis; and cell and
organ size control.23,24 The Bcl2 family proteins are pivotal
regulators of apoptotic cell death that are considered as
attractive targets for drug design.25
Thus, it clearly seems that, to improve the clinical
outcome in the pharmacological treatment of this refractory
tumor, drugs directed against novel tumor-specific cellular
targets and/or characterized by a more specific mechanism of
action are needed.
In this study, we have investigated the possibility that
the growth of MM cells may be influenced by CYP19A1.
NCI-H2452, MPP89, Ist-Mes1, Ist-Mes2, and MSTO-211H
cell lines were chosen as a model. Our experiments show that
MM cell lines, as well as human MM tissues, express ERs
and CYP19A1. The data produced suggest a specific role of
the CYP19A1 in the growth of MM. Furthermore, the anti-
proliferative action of exemestane provides strong evidence
that anti-CYP19A1 drugs inhibit tumor growth and may be a
novel strategy to sensitize the MM cells to standard therapy.
MATERIALS AND METHODS
Cell Lines
The human MM cell lines MSTO-211H and NCI-
H2452 were obtained from the American Type Culture Col-
lection (ATCC) (Rockville, MD). Cells were cultured as
monolayers in flasks using American Type Culture Collection
complete growth medium in a humidified atmosphere con-
taining 5% CO2 at 37°C. The human MM cell lines Ist-Mes1,
Ist-Mes2, and MPP89 were from Genova Institute Culture
Collection. Ist-Mes1 and Ist-Mes2 were replaced by Dul-
becco modified eagle medium with piruvate supplemented
with 10% fetal bovine serum, glutamine (2 mM) 1% nones-
sential amino acids, and antibiotics (0.02 IU/ml penicillin and
0.02 mg/ml streptomycin), whereas the established cell line,
MPP89, was maintained in Ham’s F10 with 15% fetal bovine
serum and supplemented with glutamine (2 mM) and antibi-
otics (0.02 IU/ml penicillin and 0.02 mg/ml streptomycin in
a humidified atmosphere containing 5% CO2 at 37°C).
Protein Extraction and Western Blot Analysis
Cell lysates were prepared by treating cells with ice-
cold lysis buffer (20mM Tris pH 8, 1% NP40, 10% glycerol,
137 mM NaCl, 10 mM ethylenediaminetetraacetic acid, and
inhibitor of protease and phosphatase) for 20 minutes fol-
lowed by centrifugation at 4°C for 15 minutes. Proteins (80
g) were separated on 10% sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis gels and then transferred on
polyvinylidenedifluoride membrane. Membranes were incu-
bated with antibodies of interest. Goat anti-mouse/rabbit
immunoglobulin-G horseradish peroxidase-conjugated sec-
ondary antibodies (1:3000) (Bio-Rad Laboratories; Hercules,
CA) were used. Antibody reaction was visualized using ECL
Western blotting detection reagents (Amersham-Pharmacia,
Uppsala, Sweden). Membranes were stripped by incubation
in 1 M Tris-HCl (pH 6.8), 10% sodium dodecyl sulfate, and
10 mM dithiothreitol for 30 minutes at 55°C, and reprobed
with different antibodies. The blots were, then, reacted with
ECL Western blotting detection reagents. Actin was used as
a loading control. The experiments were performed in tripli-
cate. Proteins were probed with antibodies against
CYP19A1(Santa Cruz Biotechnology, Santa Cruz, CA), anti-
ER (F-10) (Santa Cruz Biotechnology, Santa Cruz, CA),
anti-ER1 (Serotec), anti-Akt, and phosphorylation of Akt
(p-Akt) (Cell Signaling Technology, Danvers, MA) anti-
Bcl-xL (Cell Signaling Technology) anti-caspase-3 (E-8)
(Santa Cruz Biotechnology, Santa Cruz, CA), anti-poly-
(ADP-ribose)polymerase (PARP) (Cell Signaling Technol-
ogy), and with antiactin antibody (Sigma, St. Louis, MO) to
normalize the sample loading and then detected with horse-
radish peroxidase-conjugated secondary antibodies from
Santa Cruz Biotechnology, Santa Cruz, CA. The experiments
were done in triplicate.
RNA Isolation and Reverse Transcription
Polymerase Chain Reaction Assay of CYP19A1
Total RNA was prepared from cultured MPP89, Ist-
Mes2, NCI-H2452, MSTO-211H, and Ist-Mes2 using TRIzol
Reagent (Invitrogen Life Technologies, Paisley, UK) accord-
ing to the manufacturer’s protocols as described.26 Briefly,
reverse transcription of RNA, for first-strand complementary
DNA (cDNA) synthesis was performed using 4 g total RNA
and 0.5 g oligo (dT) 12 to 18 primer (Invitrogen Life
Technologies, Paisley, UK), 10 mM deoxynucleotidetriphos-
phate mix (Invitrogen Life Technologies, Paisley, UK) in a
final volume of 12 l. The reaction was incubated at 70°C for
10 minutes and immediately chilled on ice. Primer extension
was then performed 10 minutes at temperature room and 42°C
for 2 minutes after addition of first-strand buffer, 10 mM
dithiothreitol, and 40 U RNase OUT Recombinant Ribonuclease
Inhibitor (Invitrogen Life Technologies, Paisley, UK) in a final
volume of 19 l. Then 1 l (200U) SuperScript II Reverse
Transcriptase (Invitrogen Life Technologies, Paisley, UK) was
added and incubated at 42°C for 50 minutes. The reaction was
inactivated by heating at 70°C for10 minutes. cDNA was stored
at 20°C.
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Quantitative polymerase chain reaction (PCR) was con-
ducted in a volume of 25 l containing 40 ng cDNA (1/100
dilution of reverse transcription mixture), 1.25 l of
CYP19A1 primer, and 12.5 l TaqMan Universal PCR Mas-
ter Mix (Applied Biosystems, Foster City, CA) in the follow-
ing sequence: 2 minutes at 50°C and denaturation for 10
minutes at 95°C followed by 40 cycles of the amplification
step at 95° for 15 seconds (denaturation) and then at 60°C for
60 seconds (annealing/extension) in 96-well plates with the
ABI PRISM 7000 sequence Detection System (Applied Bio-
systems, Foster City, CA). Quantitative PCR for the endog-
enous control glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was carried out under the same conditions, using a
GADPH Assay on Demand (Applied Biosystems, Foster
City, CA). A standard curve for CYP19A1 was constructed
using serial dilutions (200-40-8-1.6 ng) of a pool of cDNAs
from MM cells. Results have been analyzed using the Ap-
plied Biosystems analysis software and expression levels
calculated from a linear regression of the standard curve.
Results are given as CYP19A1 gene expression versus
GAPDH expression to correct for differences in the quantity
of cDNA used in the PCR reaction. All quantitative PCR
reactions for each sample were performed in triplicate.
Cell Stimulation by Cytokine
Subconfluent MM cells were stimulated with a mixture
of cytokines (cytomix) as described.27 Briefly, cytomix (14
ng/ml TNF-, Alexis Biochemical, Lausen, Switzerland), 1
ng/l IL-1beta (Alexis Biochemical), 27 ng/ml human inter-
feron gamma (PBL Biochemical Laboratories, Piscataway,
NJ), and 160 ng lipopolysaccharide (Alexis Biochemical)
were added to cell medium for 3 hours. Then, the cells were
removed by trypsin for mRNA extraction. Controls were
treated in the same manner without cytomix. Experiments in
each MM cell line were repeated three times.
CYP19A1 Activity
As CYP19A1 catalyzes conversion of androstenedione
and testosterone to estrone and estradiol, respectively, its
activity was determined by production of estradiol after
treatment with testosterone. Cells were plated in medium
complete and the day after were treated with 10 nM testos-
terone (Sigma, St. Louis, MO) alone and in association with
10 nM PGE2 or EGF (Sigma, St. Louis, MO) for 24 hours.
Then, supernatant fluids were harvested and frozen at80°C.
CYP19A1 activity was measured by a competitive enzyme
immunoassay, Estradiol 17 EIA kit (ALPCO Diagnostics,
Windham, NH). This kit was used for quantitative determi-
nation of estradiol in culture supernatant. This kit was based
on a competitive enzyme immunoassay for quantitative de-
termination of estradiol in culture supernatant.
Clinical Data and Tumor Specimen Acquisition
All patients were treated at the Second University of
Naples between 1980 and 1996. Clinical data were obtained
by retrospective chart review. Survival was determined from
the date of initial surgery. Indeed, surgery/biopsy was the first
step of diagnosis in all patients. As a consequence, surgery/
biopsy and diagnosis were overlapped. Follow-up was avail-
able for all patients. Two subjects who died of causes other
than mesothelioma during the follow-up period were ex-
cluded from the study. All patients were treated at least with
cytoreductive surgery, and 13 patients were then treated with
radiotherapy or chemotherapy. Tissues from 29 MM speci-
mens (16 epithelioid, six sarcomatoid, and seven biphasic
mesothelioma) obtained from open biopsies or pleurectomies
were collected and fixed in 10% formalin before being
embedded in paraffin.
Histology
The formalin-fixed, paraffin-embedded samples were
sectioned at 5 m and stained with hematoxylin and eosin.
The histological diagnosis was reexamined by a pathologist
(A.B.) according to the World Health Organization (Histo-
logical typing of tumors, 2004). In addition, the most repre-
sentative blocks were selected to be cut into new 5-m-thick
sections for immunohistochemical studies.
Immunohistochemistry
All 29 cases have been assessed by immunohistochem-
istry for the presence of CYP19A1. Sections from each
specimen were cut at 5 m, mounted on glass, and dried
overnight at 37°C. All sections were then deparaffinized in
xylene, rehydrated through a graded alcohol series, and
washed in phosphate-buffered saline (PBS). PBS was used
for all subsequent washes and for antibody dilution. Endog-
enous peroxidase activity was blocked by 5% hydrogen
peroxide. The goat antihuman CYP19A1 (CYP19A1A) anti-
body C-16 (Santa Cruz Biotechnology Inc., Santa Cruz, CA)
was applied at 4°C for 12 hours at the dilution of 1:100 after
antigen retrieval in citrate buffer in a pressure cooker for 5
minutes. The optimal working dilution was defined on the
basis of titration experiments. Then, the sections were immu-
nostained with the streptavidin-biotin system (Dako, Carpin-
tera, CA), using diaminobenzidine as the final chromogen and
hematoxylin as the nuclear counterstain. Negative controls
for each tissue section were prepared by leaving out the
primary antibody. A suitable positive control was run with
each set of slides. All samples were processed under the same
conditions. Cytoplasmic CYP19A1 staining was determined
based on staining intensity (0, below the level of detection; 1,
weak; 2, moderate; and 3, strong).
In Vitro Cytotoxicity Assays and Flow
Cytometric Analysis
The in vitro drug sensitivity was assessed by Cell
Proliferation kit (XTT) (Roche Molecular Biochemicals, In-
dianapolis, IN), a colorimetric method based on the tetrazo-
lium salt (XTT), using the manufacturer’s instructions. Cells
were seeded at 2500 to 20,000 cells/well in 96-well flat-
bottomed plate (Corning Inc., Corning, NY) to allow expo-
nential growth for the 3 days of the assay to give an absor-
bance of 1.0 to 2.2. The optimum number of cells required to
reach an absorbance between 1.0 and 2.2 was determined for
each cell line (data not shown). In a typical experiment, cells
were trypsinized, seeded in 96-well plates, and allowed to
recover for 24 hours before the addition of exemestane
(Sequoia research product, UK). Drug concentrations ranged
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from 2.8  104 to 2.8  101 mM. All experimental points
were quantified fivefold. Every single point was compared
with the respective control with the same amount of DMSO.
All experiments were repeated three times. The assay was
developed after 48-hour incubation, and the absorbance was
then measured.
Cell cycle analysis was performed by flow cytom-
etry. Cells were washed in PBS and fixed in 70% ethanol
in PBS; 1  106 cells were pelleted and resuspended in a
staining solution (5.0 g/ml propidium iodide, 75 KU/ml
RNase A in PBS) for 30 minutes at room temperature in
the dark and analyzed by flow cytometry using FACScali-
bur (Becton-Dickinson Immunocytometry System-BDIS,
San Jose, CA). For each analysis, 20,000 events were
collected. Cell cycle distribution and percentage of apo-
ptotic cells were analyzed using Cell Quest (BDIS) and
ModFit LT (Verity Software House, Topsham, ME).
Statistical Analysis
Comparisons of treatment outcome were tested for statis-
tical differences using the Student’s t test for paired data.
Statistical significance were assumed at a p value of 0.05.
Fisher’s exact test was used to assess relationship
between ordinal data (correlation matrix between immuno-
staining parameters). An univariate survival analysis for each
prognostic variable on overall survival was estimated accord-
ing to the Kaplan-Meier method. The terminal event was
death attributable to cancer. The statistical significance of the
differences in survival distribution among the prognostic
groups was evaluated by the log-rank test. p values less than
0.05 was regarded as statistical significant in two-tailed tests.
SPSS software (version 10.00, SPSS, Chicago, IL) was used
for statistical analysis.
RESULTS
CYP19A1 and ER Expression in MM Cell Lines
CYP19A1, ER, and ER protein expressions were
assessed by Western blotting in MM cells, using as a control
the breast cancer cell line MCF-7. In particular, CYP19A1
was detected in all MM cell lines, as well as in MCF-7 cells,
displaying a molecular size of 54 kDa6 (Figure 1A).
The classic 67 kDa and a variant 46 kDa of ER
(Figure 1B) were expressed in MM cell lines and in MCF-7
cells.4 A variant ER 46 was identified in MCF-7 in which it
was coexpressed with the ER 66.28 Interestingly, expression
of ER 46 has been also reported in osteoclasts29 and endo-
thelial cells.30,31 No information exists on the function of
ER 46 in epithelia breast cancer cells but is known that ER
66/ER 46 ratio change with the cell growth status of the
MCF-7 cell lines.28 For this study, the MM and MCF-7 cell
extract from nonconfluent (20% confluence) cells growing in
normal serum were evaluated for ER protein content by
Western blot analysis. Results showed an excess of the ER
46 compared with ER 66. The ER forms at predominantly
59 kDa (Figure 1C) were detected in all cell lines. To further
confirm these findings, reverse transcription PCR was used to
detect CYP19A1 in MM cell lines (Figure 1D).
CYP19A1 Activity in MM Cell Lines
The CYP19A1 activity was measured in the medium of
MM cell lines before and after the addition of 10 nM
testosterone. With the exception of MPP89 and MSTO-211H,
difference between treatment and control was not observed,
leading us to believe that the levels of testosterone in the
medium were sufficient to stimulate the activity of
CYP19A1. Subsequently, on testosterone treatment, we
tested the effect of PGE2 or EGF addition, on CYP19A1
activity. Figure 2A shows a significant increase of CYP19A1
activity in MPP89, Ist-Mes2, and Ist-Mes1 after EGF and
PGE2 stimulation. PGE2 induced an increase in CYP19A1
activity in NCI-H2452 and MSTO-211H, whereas in the
same cell lines, EGF had no effect. The effect of cytokines on
FIGURE 1. Aromatase and estrogen receptors are expressed
in human mesothelioma cells. A, Using gel electrophoresis
with Western blot, CYP19A1 expression is shown in five rep-
resentative malignant mesothelioma (MM) cell lines. Breast
cancer cell line MCF-7 with known expression of CYP19A1,
positive control. MPP89, Ist-Mes2, NCI-H2452, MSTO-211H,
and Ist-Mes1 MM cell lines as noted. B, Using electrophore-
sis and Western blot, ER expression is shown in five repre-
sentative MM cell lines and MCF-7, positive control with
known high expression of Er. The classical 67 KDa ER, as
well as a 46 KDa variant, occurs in MCF-7and MM cell lines.
C, Using electrophoresis with Western blot, expression of
ER is shown in MM cell lines and MCF7, positive control.
Bottom, actin loading controls. Multiple signals were
achieved by stripping and reprobing the same blot. D, Re-
verse transcription polymerase chain reaction (RT-PCR) am-
plification for assay of aromatase mRNA from MCF7and MM
cells. mRNA CYP indicates aromatase gene expression versus
GAPDH. The standard deviation expresses the result of three
different quantization. Note that the same representative
MM cancer cell lines were used for RT-PCR and for Western
immunoblots.
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the CYP19A1 mRNA level and activity of CYP19A1 were
tested in MM cell lines. Cytokines increased CYP19A1
mRNA in MPP89 and Ist-Mes2 after 3 hours of treatment. In
Ist-Mes1, the effect was observed already after 1 hour (Figure
2B). In all cell lines, the CYP19A1 activity was measured
after 3 hours of treatment with cytomix. At this time, a
TABLE 1. Characteristics of the Patients Enrolled in the
Study
Patients Histology
Score Aromatase
(0  Absent; 1  Low;
and 2  High)
Survival
Time (mo)
1 Epithelial 1 18
2 Epithelial 0 15
3 Epithelial 2 6
4 Epithelial 2 1
5 Epithelial 1 12
6 Epithelial 2 10
7 Epithelial 0 18
8 Epithelial 2 9
9 Epithelial 2 7
10 Epithelial 1 14
11 Epithelial 0 13
12 Epithelial 2 4
13 Epithelial 2 3
14 Epithelial 2 5
15 Epithelial 2 10
16 Epithelial 1 14
17 Sarcomatoid 0 9
18 Sarcomatoid 2 3
19 Sarcomatoid 2 5
20 Sarcomatoid 2 4
21 Sarcomatoid 2 8
22 Sarcomatoid 0 16
23 Biphasic 2 6
24 Biphasic 2 4
25 Biphasic 2 1
26 Biphasic 2 11
27 Biphasic 2 9
28 Biphasic 2 15
29 Biphasic 2 8
level after treatment with cytomix at 1, 2, and 3 hours. Lev-
els of CYP19A1 mRNA were compared with that in MM cells
not treated with cytomix. Values were reported as means 
SD of three independent experiments, and p value indicates
significant difference (p  0.05) of the treatment with cyto-
kines versus control calculated by Student’s t test. C, Effect
of cytokines in MM cell lines was measured by production of
estradiol after treatment with cytomix at 3 hours. Aromatase
activity in MM cells was measured by production of estradiol
after treatment with cytomix at 3 hours. See text for details.
Values were reported as means  SD of three independent
experiments, and p values indicate significant difference
(p  0.05) of the treatment with cytokines versus control
calculated by Student’s t test.
FIGURE 2. Aromatase activity occurs in human malignant
mesothelioma (MM) cells. A, Aromatase activity in MM cells
was measured by production of estradiol after treatment
with testosterone. The greatest increment in the production
of estradiol occurred after 48 hours treatment with 10
nmol/L testosterone and prostaglandin-E2 (PGE2) in all MM
cell lines. Testosterone in combination with epidermal
growth factor (EGF) induced a statistically significant in-
crease in aromatase activity in MPP89, Ist-Mes2 and Ist-
Mes1. Estradiol standards were provided by the manufac-
turer, and controls included cells grown but not treated with
testosterone. Values were reported as means  SD of three
independent experiments, and asterisks indicate significant
difference (p  0.05) of the treatment with EGF or PGE2
versus testosterone calculated by Student’s t test. B, Effect of
cytokines in MM cell lines was measured by CYP19A1 mRNA
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significant increase in CYP19A1 activity was determined in
Ist-Mes1 and MPP89 (Figure 2C).
Analysis of CYP19A1 Expression in Human
Mesothelioma Samples
Table 1 presents the characteristics of the patients
enrolled in this study and summary results from immunohis-
tochemical analysis of the 29 mesothelioma specimens. His-
tologically, tumor specimens contained 16 epithelioid, six
sarcomatoid, and seven biphasic mesothelioma. CYP19A1
staining was either negative or cytoplasmic. Figure 3A pre-
sents some typical immunohistochemical staining for
CYP19A1. Normal mesothelium exhibited a weak positivity
for CYP19A1 (data not shown). By rank correlation matrix,
correlation has been recorded between immunohistochemical
parameters and mesothelioma histology type. These results
are summarized in Figure 3B. By univariate analysis, overall
survival seems to be influenced by CYP19A1 expression. The
median survival in patients with low to absent CYP19A1
expression was longer than in those patients with high
CYP19A1 expression (p  0.001). Interestingly, the histo-
logic type did not influence the overall survival in our patients’
population. These data are summarized in Figure 3C. Figure 4
depicts Kaplan-Meier survival plots for all patients showing a
statistically significant association between high expression of
CYP19A1 and poor outcome (p  0.001).
In Vitro Cytotoxicity Assays and Flow
Cytometric Analysis
To assess direct effects on an CYP19A1 inhibitor on
mesothelioma cell proliferation, tumor cells were treated
without or with exemestane (doses ranging from 0 to 2.8 
101 mM) in vitro. Cell growth of MM cells was determined
by the cell proliferation kit in MPP89, Ist-Mes1, and Ist-
Mes2. In these cell lines, CYP19A1 activity was up-regulated
by PGE2 and EGF and, therefore, similar to experimental
models of breast cancer in which aromatase inhibitors are
effective. Figure 5A shows the effect of dose-dependent
exemestane on the survival of MM cells. To analyze whether
inhibition of cell growth by treatment with exemestane in
mesothelioma cell lines was accompanied by alterations
in cell cycle distribution, we analyzed the percentage of cells
in the different stages of cell cycle by flow cytometry. Figure
5B shows the histograms of DNA content in MPP, Ist-Mes1,
and Ist-Mes2 cells treated with 2.8  101 mM of exemes-
tane for 48 hours. Analysis of cell percentages in the different
phases of the cell cycle revealed that exemestane induces an
accumulation of cells in the S-G2/M proliferative compart-
ments of the cell cycle with the concomitant decrease in the
G0/G1 phase in all the lines used. Moreover, a fraction of cell
population resides to the sub-G1 compartment, suggesting
that exemestane also induced cell death. Western blot anal-
ysis showed that there was activation of caspase-3 and PARP
in MM treated with 2.8  101 mM of exemestane (Figure
5C). Taken together, exemestane induces apoptosis in MM
cells. Figure 5C shows a significant decreasing of Bcl-xL in
both cell lines and strongly inhibited constitutive p-AKT
in Ist-Mes-1 and MPP89. No basal p-AKT was detected in
Ist-Mes-2 cell line.26
DISCUSSION
MM is one of the most lethal human tumors. Recent
randomized studies on the treatment of mesothelioma with
combined chemotherapy demonstrated a survival benefit
FIGURE 3. Aromatase expression by immunohistochemistry
is present in most archival malignant mesothelioma (MM)
tumor specimens. A, Immunohistochemical staining of aro-
matase in human pleural mesothelioma. 1  strong cyto-
plasmic expression (original magnification, 200); 2  neg-
ative staining (original magnification, 200). B, Correlation
between aromatase expression and histotype. C, Survival
and pathological and immunohistochemical parameters in
patients with MM in an univariate analysis.
FIGURE 4. Kaplan-Meier survival plot for aromatase.
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when a combination of cisplatin and antifolate drugs was
used32,33 and when surgery was supplemented by postopera-
tive radiotherapy in patients who underwent incomplete re-
section.34 Unfortunately, none of those forms of treatment
had a significant impact on the progression and outcome of
mesothelioma, and new therapeutic approaches must be in-
vestigated for a more successful treatment of this disease.
In this scenario, we demonstrated the presence of CYP19A1
in MM cell lines and in a group of samples from patients with
MM. Furthermore, ER and ER were also detected in MM
cell lines. This finding was confirmed by evidences support-
ing a role of ER expression in MM.35 Over the last decade,
many studies have been carried out to identify potential
CYP19A1 stimulatory factors: IL-6 was the most potent
factor detected that could stimulate CYP19A1 activity.36
Other cytokines and growth factors can stimulate CYP19A1
activity.37 Notable, in our experimental setting, the stimula-
tion with cytomix induced an increase of CYP19A1 mRNA
levels. It is well known that expression of the CYP19A1 gene
is regulated in a tissue-specific manner by the use of alterna-
tive promoters.38 PGE2 is thought to be an important regu-
lator of CYP19A1 gene expression.39 Interestingly, we found
that PGE2 increased CYP19A1 activity level in all five MM
cell lines. A growing number of reports on the tumor biology
of MMs have identified many cytokines involved in tumor
growth or the spread of this disease.40–44
The MM cell lines were capable of releasing a consti-
tutively high amount of IL-6 (1100 pg/ml/supernatant of
confluent cultures).45 This could explain the presence of
CYP19A1 in MM cells. On the other hand, previous studies
have shown that CYP19A1 is present and biologically active
in human non-small cell lung cancer cell and that tumor
growth can be down-regulated by specific inhibition of
CYP19A1.46
To investigate whether these in vitro observations could
have some clinical relevance, we decided to analyze
CYP19A1 expression in a group of human MM samples. We
found that CYP19A1 was expressed in the majority of MM
samples as a cytoplasmic protein. Interestingly, the cytoplas-
mic expression of CYP19A1 significantly correlated with
poor survival. The World Health Organization classifies MM
into epithelial, sarcomatoid, and biphasic types, each of
which can be subdivided further.47 This classification has
implications for both diagnosis and prognosis. Prognosis is
poor for all MMs, but sarcomatoid MMs have a particularly
poor response rate to treatment.48 Interestingly, a significant
association between high expression of CYP19A1 and sarco-
the different phases of cell cycle was reported inside the rel-
ative histogram. A representative out of three independent
experiments is shown. C, Effect of exemestane (Exe) on
caspase-3, poly(ADP-ribose) polymerase (PARP), Bcl-xL, and
phosphorylation of Akt (p-Akt). The cells were cultured in com-
plete medium for 24 hours and then treated with exemestane
(2.8  101 mM) for 48 hours. Western blot of total lysates
indicates that the addition of exemestane activates caspase
pathways and PARP cleavage and significantly decreases p-Akt and
Bcl-xL. Ist-Mes2 has no detectable basal p-Akt.
FIGURE 5. Aromatase inhibitor, exemestane, blocks growth
of malignant mesothelioma (MM) cell in vitro. A, Exemes-
tane reduces growth of MPP89, Ist-Mes1, and Ist-Mes2 cell
lines in vitro. Both cell lines were treated with exemestane
for 48 hours (72 hours after seeding the cells in flask) at
concentrations ranging from 2.8  104 to 2.8  101mM.
B, Effect of exemestane on the cell cycle in MM cell lines.
Cell cycle analysis after propidium iodide staining was per-
formed by flow cytometry in MPP89 (white histograms), Ist-
Mes1 (gray histograms), and Ist-Mes2 (black histograms)
cells untreated or treated with exemestane at the dose of
2.8  101 mM for 48 hours. The percentages of cells in
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matoid MMs was found. These observations strongly suggest
that CYP19A1 plays a role in tumor progression in MM. It
must be noted that the data described are retrospective and
essentially observational in nature, and, therefore, they can-
not explain functional mechanisms by which CYP19A1 ac-
tually promotes tumor growth. Therefore, additional studies
performed with larger independent groups of patients are
needed to decipher the role of CYP19A1 expression in MM
progression. Nevertheless, in vitro and in vivo data on patient
strongly suggest that the CYP19A1 can be an interestingly
therapeutic target for MM. To test whether CYP19A1 inhib-
itors reduce mesothelioma cell growth, MM cell lines were
treated with exemestane, a type I CYP19A1 inhibitor that
irreversible binds to the CYP19A1 enzyme, causing perma-
nent inactivation. In our study, mesothelioma cell prolifera-
tion was significantly reduced by exemestane treatment in all
the lines used. Inhibition of cell proliferation well correlated
with the perturbation of cell cycle induced by exemestane.
Specifically, we found that inhibition of CYP19A1 caused a
block of cells in S-G2M phase of cell cycle. We speculate
that exemestane-induced proliferative block was irreversible
as a significative increase of a population with a sub-G1 DNA
content that are indicative of apoptosis was observed in the
treated compared with untreated cells. Evidence of apoptosis
in MM cells on exemestane treatment was observed in West-
ern blot. Exemestane induces apoptosis by caspase-dependent
pathway. In our experiments, caspase activation and PARP
cleavage were detected in MM cell lines. The prosurvival
BclII family members, such as Bcl-xL and Bcl2, are pivotal
regulators of apoptotic cell death that are considered as
attractive targets for drug design.25,31 Exemestane induces in
MM cell lines a down-regulation of Bcl-xL. Recent reports
have indicated that activation of Akt pathway is implicated in
conferring resistance to conventional chemotherapy and mul-
tiple chemotherapeutic agents (5-fluorouracil, adriamycin,
mitomycin C, and cisplatinum) on cancer cells.49,50 Akt is
hyperactivated in a wide range of human tumors as a result of
constitutive activation of growth receptors, mutation of phos-
phatidylinositol 3-kinase, and inactivation or loss of phospha-
tase and tensin homolog phosphatase.21 Exemestane induces
in MM cell lines a down-regulation of p-Akt. Overall, these
data lead us to believe that this CYP19A1 inhibitor can be
used to sensitize the cells to standard therapy. The combina-
tion of chemotherapy with antiestrogen has been already
exploited in clinical trials on patients with MM.51 A phase III
trial comparing maximum debulking surgery and postopera-
tive cisplatin, interferon alpha-2b, and tamoxifen immuno-
chemotherapy with and without intraoperative photodynamic
therapy was described. The results indicate that the aggres-
sive multimodal therapy can be delivered for patients with
higher stage MM.52
Finally, it must be underlined that the analysis of
CYP19A1 expression was performed on a small number of
patients treated heterogeneously; therefore, further studies are
urgently required both in vitro and in vivo level to confirm
these observations and eventually to propose exemestane as a
concrete target for MM therapy.
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